The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis
AuthorsVersluis, J. M.
Hendriks, A. M.
Weppler, A. M.
Brown, L. J.
de Joode, K.
Suijkerbuijk, K. P. M.
Kapiteijn, E. W.
Johnson, D. B.
Jansen, Y. J. L.
Lorigan, Paul C
Ascierto, P. A.
Menzies, A. M.
Long, G. V.
van der Veldt, A. A. M.
Carlino, M. S.
van Tinteren, H.
de Vries, E. G. E.
Blank, C. U
AffiliationDepartment of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.
MetadataShow full item record
AbstractIntroduction: In patients with metastatic melanoma, progression of a single tumour lesion (solitary progression) after response to immune checkpoint inhibition (ICI) is increasingly treated with local therapy. We evaluated the role of local therapy for solitary progression in melanoma. Patients and methods: Patients with metastatic melanoma treated with ICI between 2010 and 2019 with solitary progression as first progressive event were included from 17 centres in 9 countries. Follow-up and survival are reported from ICI initiation. Results: We identified 294 patients with solitary progression after stable disease in 15%, partial response in 55% and complete response in 30%. The median follow-up was 43 months; the median time to solitary progression was 13 months, and the median time to subsequent progression after treatment of solitary progression (TTSP) was 33 months. The estimated 3-year overall survival (OS) was 79%; median OS was not reached. Treatment consisted of systemic therapy (18%), local therapy (36%), both combined (42%) or active surveillance (4%). In 44% of patients treated for solitary progression, no subsequent progression occurred. For solitary progression during ICI (n = 143), the median TTSP was 29 months. Both TTSP and OS were similar for local therapy, ICI continuation and both combined. For solitary progression post ICI (n = 151), the median TTSP was 35 months. TTSP was higher for ICI recommencement plus local therapy than local therapy or ICI recommencement alone (p = 0.006), without OS differences. Conclusion: Almost half of patients with melanoma treated for solitary progression after initial response to ICI had no subsequent progression. This study suggests that local therapy can benefit patients and is associated with favourable long-term outcomes.
CitationVersluis JM, Hendriks AM, Weppler AM, Brown LJ, de Joode K, Suijkerbuijk KPM, et al. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. European Journal of Cancer. 2021 Jul;151:72–83.
JournalEuropean Journal of Cancer
- Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
- Authors: Chen L, Douglass J, Kleinberg L, Ye X, Marciscano AE, Forde PM, Brahmer J, Lipson E, Sharfman W, Hammers H, Naidoo J, Bettegowda C, Lim M, Redmond KJ
- Issue date: 2018 Mar 15
- Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors.
- Authors: Kelly D, Rose AAN, Muniz TP, Hogg D, Butler MO, Saibil SD, King I, Kamil ZS, Ghazarian D, Ross K, Iafolla M, Araujo DV, Waldron J, Laperriere N, Krema H, Spreafico A
- Issue date: 2021 Jul 20
- Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma.
- Authors: Soerensen AV, Ellebaek E, Bastholt L, Schmidt H, Donia M, Svane IM
- Issue date: 2020 Sep 11
- Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
- Authors: Wang SJ, Khullar K, Kim S, Yegya-Raman N, Malhotra J, Groisberg R, Crayton SH, Silk AW, Nosher JL, Gentile MA, Mehnert JM, Jabbour SK
- Issue date: 2020 Oct
- Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma.
- Authors: Bol KF, Ellebaek E, Hoejberg L, Bagger MM, Larsen MS, Klausen TW, Køhler UH, Schmidt H, Bastholt L, Kiilgaard JF, Donia M, Svane IM
- Issue date: 2019 Oct 3